| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors |
201 |
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes |
184 |
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Introduction and Other Protein Targets |
151 |
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels |
115 |
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors |
78 |
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters |
62 |
| Opioids and the immune system - friend or foe |
57 |
| THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors |
54 |
| New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation |
47 |
| Drug repurposing from the perspective of pharmaceutical companies |
42 |
| Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities |
42 |
| Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25 |
41 |
| Targeting nociceptive transient receptor potential channels to treat chronic pain: current state of the field |
38 |
| PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery |
36 |
| The novel mu-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception |
36 |
| Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases |
35 |
| Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors |
34 |
| Reactive oxygen species: key regulators in vascular health and diseases |
33 |
| Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/beta-catenin pathway against renal fibrosis |
30 |
| P2X receptor channels in chronic pain pathways |
28 |
| Drug repurposing screens and synergistic drug-combinations for infectious diseases |
24 |
| Adipokines and inflammation: is it a question of weight? |
24 |
| Identification and structure elucidation of the pro-resolving mediators provides novel leads for resolution pharmacology |
24 |
| Anti-inflammatory therapies in myocardial infarction: failures, hopes and challenges |
24 |
| Melatonin receptors: molecular pharmacology and signalling in the context of system bias |
22 |
| Tetramethylpyrazine nitrone activates the BDNF/Akt/CREB pathway to promote post-ischaemic neuroregeneration and recovery of neurological functions in rats |
21 |
| Endoplasmic reticulum stress in the heart: insights into mechanisms and drug targets |
21 |
| Multiple role of 3-mercaptopyruvate sulfurtransferase: antioxidative function, H2S and polysulfide production and possible SOx production |
20 |
| Endothelial NOS: perspective and recent developments |
20 |
| Speciation of reactive sulfur species and their reactions with alkylating agents: do we have any clue about what is present inside the cell? |
19 |
| Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy |
19 |
| Immune-pineal axis - acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes |
19 |
| Anti-tumour actions of cannabinoids |
18 |
| Protein S-sulfhydration by hydrogen sulfide in cardiovascular system |
18 |
| Hydrogen sulfide pretreatment improves mitochondrial function in myocardial hypertrophy via a SIRT3-dependent manner |
18 |
| Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system |
18 |
| Opioid system and human emotions |
18 |
| Influence of opioids on immune function in patients with cancer pain: from bench to bedside |
17 |
| NO as a multimodal transmitter in the brain: discovery and current status |
17 |
| Nuciferine ameliorates hepatic steatosis in high-fat diet/streptozocin-induced diabetic mice through a PPAR alpha/PPAR gamma coactivator-1 alpha pathway |
17 |
| Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome |
17 |
| Berberine attenuates hepatic steatosis and enhances energy expenditure in mice by inducing autophagy and fibroblast growth factor 21 |
17 |
| The extracellular matrix as a key regulator of intracellular signalling networks |
17 |
| Role of immune cells in hypertension |
17 |
| Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs |
17 |
| Melatonin in regulation of inflammatory pathways in rheumatoid arthritis and osteoarthritis: involvement of circadian clock genes |
16 |
| The role of Hippo/yes-associated protein signalling in vascular remodelling associated with cardiovascular disease |
16 |
| Diosmetin induces apoptosis and enhances the chemotherapeutic efficacy of paclitaxel in non-small cell lung cancer cells via Nrf2 inhibition |
16 |
| Glycycoumarin protects mice against acetaminophen-induced liver injury predominantly via activating sustained autophagy |
16 |
| GPCR signalling from within the cell |
16 |
